438
Participants
Start Date
September 23, 2021
Primary Completion Date
April 30, 2024
Study Completion Date
April 30, 2024
Intravenous glenzocimab (ACT017) 1000 mg
Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Intravenous Placebo
Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Northside hospital, St. Petersburg
Black Medical center, Bradenton
Nova Clinical Research, Bradenton
Chattanooga center for neurological research, Chattanooga
University Clinic Essen, Essen
Miami Valley hospital, Dayton
University of Chicago, Chicago
Washington university, St Louis
Houston Methodist hospital, Houston
Memorial Hermann Hospital, Houston
Lead Sponsor
Acticor Biotech
INDUSTRY